| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
IMP2-IN-2 selectively targets IMP2, an RNA-binding protein that binds to and stabilizes target mRNAs, including those involved in cell proliferation and metabolism. The inhibitor disrupts the interaction between IMP2 and its RNA targets, with IC50 values of 120.9 microM and 236.7 microM for RNA_A and RNA_B, respectively.
|
|---|---|
| ln Vitro |
IMP2-IN-2 potently inhibits the interaction of IMP2 with its target RNA sequences (RNA_A and RNA_B) with IC50 values of 120.9 microM and 236.7 microM, respectively. By disrupting IMP2-RNA binding, the compound aims to reduce tumor progression, metastasis, and cellular responses associated with abnormal cell proliferation.
|
| ln Vivo |
Dedicated in vivo efficacy studies for IMP2-IN-2 are not extensively documented in standard profiles. As the first-in-class small molecule inhibitor of IMP2, it is hypothesized to reduce tumor growth in animal models. Detailed in vivo data are not publicly available but are expected from ongoing research.
|
| Enzyme Assay |
The inhibitory activity of IMP2-IN-2 is measured using an in vitro RNA-binding assay. Recombinant IMP2 protein is incubated with labeled target RNA sequences (RNA_A and RNA_B) in the presence of varying concentrations of the compound. The bound RNA is captured and quantified to calculate the IC50 values.
|
| Cell Assay |
Cancer cell lines are cultured and treated with IMP2-IN-2. The effect on IMP2 target gene expression is assessed by qPCR or Western blot. Cell proliferation and viability are measured by MTT or CellTiter-Glo assays. The compound's ability to reduce cell migration and invasion can also be assessed.
|
| Animal Protocol |
Dedicated in vivo protocols for IMP2-IN-2 are not well-documented. A standard protocol would involve establishing subcutaneous tumor xenografts in immunodeficient mice. The compound would be administered via intraperitoneal injection. Tumor growth and IMP2 target gene expression would be monitored.
|
| ADME/Pharmacokinetics |
Detailed PK parameters for IMP2-IN-2 are not extensively documented. As a small molecule with a molecular weight of 448.46 g/mol, its physicochemical properties may support in vivo applications. Comprehensive ADME data are not publicly reported.
|
| Toxicity/Toxicokinetics |
Toxicological data for IMP2-IN-2 are not available in standard profiles. As a first-in-class research compound, comprehensive toxicology studies have not been publicly reported. Standard laboratory safety precautions apply.
|
| References | |
| Additional Infomation |
IMP2-IN-2 is the first small-molecule inhibitor targeting the RNA-binding protein IMP2. It represents a novel approach to cancer therapy by disrupting protein-RNA interactions rather than traditional enzyme active sites. The compound is a valuable chemical probe for studying IMP2 biology.
|
| Exact Mass |
448.107
|
|---|---|
| CAS # |
1448353-39-6
|
| PubChem CID |
71739693
|
| Appearance |
Off-white to light yellow solid powder
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
31
|
| Complexity |
620
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCN(CC1=CC=CC=C1)C(=O)NC2=C(SC(=C2)C3=CC=C(C=C3)C(F)(F)F)C(=O)O
|
| InChi Key |
SNHWNAMJHQFCTE-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C22H19F3N2O3S/c1-2-27(13-14-6-4-3-5-7-14)21(30)26-17-12-18(31-19(17)20(28)29)15-8-10-16(11-9-15)22(23,24)25/h3-12H,2,13H2,1H3,(H,26,30)(H,28,29)
|
| Chemical Name |
3-[[benzyl(ethyl)carbamoyl]amino]-5-[4-(trifluoromethyl)phenyl]thiophene-2-carboxylic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
